Literature DB >> 9797861

Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent.

R Kondo1, M A Feitelson, D S Strayer.   

Abstract

We have described a novel gene transfer system, in which replication-incompetent, T antigen-deleted simian virus-40 (SV40) is used as the transduction vehicle. We report here successful immunization using such an SV40-derived viral vector. Hepatitis B surface antigen (HBsAg) cDNA was cloned downstream of two tandem SV40 early promoters to yield a T antigen-deficient SV40 derivative, SV(HBS). Cultured TC7 cells were exposed to SV(HBS), and expression of HBsAg was detected 24 h later by Northern blot and RT-PCR analysis. Immunochemistry and Western blot analysis were also performed 24 h after infection to detect expression of HBsAg. Once it was ascertained that we could express HBsAg in this way, we used SV(HBS) to elicit anti-HBs. SV(HBS) was injected intraperitoneally or subcutaneously into mice every 4 weeks. These mice were bled every 2 weeks and their sera assayed for antibody activity against HBsAg and SV40. Production of anti-HBs was measured by ELISA and confirmed by Western blot analysis, both of which demonstrated significant levels of anti-HBs after the second injection. We also tested production of anti-SV40 antibodies by the ability of sera to neutralize SV(HBS) infectivity. We found no evidence of neutralization of SV(HBS) infectivity even after eight inoculations. Thus, replication-incompetent SV40 is itself not a strong antigen. Our data suggest that SV40-based transduction systems may be a useful vehicle for immunization and for other gene transfer applications when a need for multiple inoculations is anticipated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797861     DOI: 10.1038/sj.gt.3300623

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

1.  pH stability and disassembly mechanism of wild-type simian virus 40.

Authors:  Roi Asor; Daniel Khaykelson; Orly Ben-Nun-Shaul; Yael Levi-Kalisman; Ariella Oppenheim; Uri Raviv
Journal:  Soft Matter       Date:  2020-02-27       Impact factor: 3.679

2.  Pseudovirions as vehicles for the delivery of siRNA.

Authors:  Paul E Lund; Ryan C Hunt; Michael M Gottesman; Chava Kimchi-Sarfaty
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

Review 3.  Long-term gene expression in dividing and nondividing cells using SV40-derived vectors.

Authors:  David S Strayer; Lokesh Agrawal; Pierre Cordelier; Bianling Liu; Jean-Pierre Louboutin; Elena Marusich; Hayley J McKee; Carmen N NiGongyi Ren; Marlene S Strayer
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.860

4.  In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.

Authors:  C Mueller; M S Strayer; J Sirninger; S Braag; F Branco; J-P Louboutin; T R Flotte; D S Strayer
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250

5.  Simian virus 40 vectors for pulmonary gene therapy.

Authors:  Luminita Eid; Zohar Bromberg; Mahmoud Abd El-Latif; Evelyn Zeira; Ariella Oppenheim; Yoram G Weiss
Journal:  Respir Res       Date:  2007-10-29

6.  DNA-free recombinant SV40 capsids protect mice from acute renal failure by inducing stress response, survival pathway and apoptotic arrest.

Authors:  Veronika Butin-Israeli; Dotan Uzi; Mahmoud Abd-El-Latif; Galina Pizov; Arieh Eden; Yosef S Haviv; Ariella Oppenheim
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

7.  High cooperativity of the SV40 major capsid protein VP1 in virus assembly.

Authors:  Santanu Mukherjee; Mahmoud Abd-El-Latif; Michal Bronstein; Orly Ben-nun-Shaul; Stanislav Kler; Ariella Oppenheim
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

8.  Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 +/- IL-15.

Authors:  Hayley J McKee; Patricia Y T'sao; Maria Vera; Puri Fortes; David S Strayer
Journal:  Genet Vaccines Ther       Date:  2004-08-23

Review 9.  How Simian Virus 40 Hijacks the Intracellular Protein Trafficking Pathway to Its Own Benefit … and Ours.

Authors:  Miguel G Toscano; Peter de Haan
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

10.  Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40.

Authors:  Xiaoxia Shi; Matthew Ryan Ykema; Jaco Hazenoot; Lysbeth Ten Bloemendaal; Irene Mancini; Machteld Odijk; Peter de Haan; Piter J Bosma
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-27       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.